bioRxiv Science⌕ Search

Biology subjects

Amidian, S.

Publications and source records attributed to Amidian, S..

2 recordsLinked to original sources

A Müller glia-retinal pigment epithelium apical network surrounding cone outer segments in fish and mouse

Homeostasis of the vertebrate retina is supported by two non-neuronal cell types, Muller glia and the retinal pigment epithelium (RPE). Their apical domains delineate the subretinal space, where photoreceptor outer segments reside. While the individual interactions between the supporting cells and photoreceptors are well studied, Muller glia and RPE are presumed to remain physically separate in a healthy retina. Here, we describe a revised model of the subretinal space architecture based on detailed FIB-SEM and confocal microscopy imaging of the zebrafish and mouse outer retina. Long apical processes extend from both Muller glia and the RPE, interacting with one another while also encircling cone outer segments. These contact regions, at the interface of the three cell types are highly elaborated in fish and, although sparser, are still present in mouse. The growth and overlap of Muller glial and RPE apical processes occurs subsequent to the emergence of the outer segment in both species, and coincides with the onset of visual function in mouse. Although enriched at cone sites, this specialized interaction does not appear to depend solely on cone localization in either species, pointing to a general hallmark of the vertebrate subretinal space. Together, our work provides major insights into the architecture of the subretinal space and the interactions between Muller glia, RPE and photoreceptors, while demonstrating conservation across species.

cell biology↗

Rational design of structure-based vaccines targeting misfolded alpha-synuclein conformers of Parkinson's disease and related disorders

BackgroundSynucleinopathies, including Parkinsons disease, multiple system atrophy, and dementia with Lewy bodies, are neurodegenerative disorders caused by the accumulation of misfolded alpha-synuclein protein. Developing effective vaccines against synucleinopathies has been challenging due to the difficulty of stimulating an immune-specific response against alpha-synuclein, conferring neuroprotection without causing harmful autoimmune reactions, and selectively targeting only pathological forms of alpha-synuclein. Previous attempts using linear peptides and epitopes without control of the antigen structure for immunization failed in clinical trials. The immune system was unable to distinguish between the native alpha-synuclein and its amyloid form. ResultsThe prion domain of the fungal HET-s protein was selected as a scaffold to introduce select epitopes from the surface of alpha-synuclein fibrils. Four vaccine candidates were generated by introducing specific amino acid substitutions onto the surface of the scaffold protein in regions that showed structural similarity to alpha-synuclein fibril structures. Each vaccine candidate had unique amino acid substitutions that imitated a specific epitope from alpha-synuclein amyloid fibrils. The approach successfully mimicked the stacking of the parallel in-register beta-sheet structure seen in alpha-synuclein fibrils as the vaccine candidates were found to be structurally stable and self-assembling into the desired conformations. All vaccine candidates induced substantial levels of IgG antibodies that recognized pathological alpha-synuclein fibrils derived from a synucleinopathy mouse model. Furthermore, the resulting anti-sera recognized pathological alpha-synuclein aggregates in brain lysates from patients who died from dementia with Lewy bodies, multiple system atrophy, or Parkinsons disease, but did not recognize linear alpha-synuclein peptides. Each vaccine candidate induced a unique pattern of reactivity toward alpha-synuclein aggregates contained in distinct disease pathologies. ConclusionsThis new approach, based on the rational design of vaccines using the secondary and tertiary structure of alpha-synuclein amyloid fibrils and strict control over the exposed antigen structure used for immunization, as well as the ability to mimic aggregated alpha-synuclein, provides a promising avenue towards developing effective vaccines against alpha-synuclein fibrils, which may be crucial for the prevention and treatment of synucleinopathies.

biochemistry↗